Literature DB >> 27020403

Role of B cells in the pathogenesis of systemic sclerosis.

S Sanges1, T Guerrier2, D Launay3, G Lefèvre4, M Labalette5, A Forestier1, V Sobanski1, J Corli6, C Hauspie2, M Jendoubi7, I Yakoub-Agha8, P-Y Hatron9, E Hachulla1, S Dubucquoi5.   

Abstract

Systemic sclerosis (SSc) is an orphan disease characterized by progressive fibrosis of the skin and internal organs. Aside from vasculopathy and fibrotic processes, its pathogenesis involves an aberrant activation of immune cells, among which B cells seem to play a significant role. Indeed, B cell homeostasis is disturbed during SSc: the memory subset is activated and displays an increased susceptibility to apoptosis, which is responsible for their decreased number. This chronic loss of B cells enhances bone marrow production of the naïve subset that accounts for their increased number in peripheral blood. This permanent activation state can be explained mainly by two mechanisms: a dysregulation of B cell receptor (BCR) signaling, and an overproduction of B cell survival signals, B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). These disturbances of B cell homeostasis induce several functional anomalies that participate in the inflammatory and fibrotic events observed during SSc: autoantibody production (some being directly pathogenic); secretion of pro-inflammatory and pro-fibrotic cytokines (interleukin-6); direct cooperation with other SSc-involved cells [fibroblasts, through transforming growth factor-β (TGF-β) signaling, and T cells]. These data justify the evaluation of anti-B cell strategies as therapeutic options for SSc, such as B cell depletion or blockage of B cell survival signaling.
Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  B cell; BAFF; CD19; Rituximab; Systemic sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27020403     DOI: 10.1016/j.revmed.2016.02.016

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  16 in total

1.  Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study.

Authors:  Aurélien Chepy; Solange Vivier; Fabrice Bray; Camille Ternynck; Jean-Pascal Meneboo; Martin Figeac; Alexandre Filiot; Lucile Guilbert; Manel Jendoubi; Christian Rolando; David Launay; Sylvain Dubucquoi; Guillemette Marot; Vincent Sobanski
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 2.  Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis.

Authors:  Jean-Luc Senécal; Sabrina Hoa; Roger Yang; Martial Koenig
Journal:  J Scleroderma Relat Disord       Date:  2019-09-09

3.  B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis.

Authors:  Sébastien Sanges; Manel Jendoubi; Niloufar Kavian; Carine Hauspie; Silvia Speca; Jean-Charles Crave; Thomas Guerrier; Guillaume Lefèvre; Vincent Sobanski; Ariel Savina; Eric Hachulla; Pierre-Yves Hatron; Myriam Labalette; Frédéric Batteux; Sylvain Dubucquoi; David Launay
Journal:  Front Immunol       Date:  2017-02-07       Impact factor: 7.561

4.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.

Authors:  M Colaci; D Giuggioli; C Vacchi; C Ferri
Journal:  Case Rep Rheumatol       Date:  2017-05-04

Review 5.  The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis.

Authors:  Aslıhan Avanoǧlu Güler; Francesca Wanda Rossi; Silvia Bellando-Randone; Nella Prevete; Abdurrahman Tufan; Mirko Manetti; Amato de Paulis; Marco Matucci-Cerinic
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

6.  Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment.

Authors:  Olga Gumkowska-Sroka; Krystyna Jagoda; Aleksander Owczarek; Grzegorz Helbig; Joanna Giemza-Stokłosa; Przemysław J Kotyla
Journal:  J Clin Med       Date:  2019-05-08       Impact factor: 4.241

7.  Alternatively activated macrophages are associated with the α2AP production that occurs with the development of dermal fibrosis : The role of alternatively activated macrophages on the development of fibrosis.

Authors:  Yosuke Kanno; En Shu; Hirofumi Niwa; Hiroyuki Kanoh; Mariko Seishima
Journal:  Arthritis Res Ther       Date:  2020-04-10       Impact factor: 5.156

8.  Inhibition of effector B cells by ibrutinib in systemic sclerosis.

Authors:  Jakob Einhaus; Ann-Christin Pecher; Elisa Asteriti; Hannes Schmid; Kathy-Ann Secker; Silke Duerr-Stoerzer; Hildegard Keppeler; Reinhild Klein; Corina Schneidawind; Joerg Henes; Dominik Schneidawind
Journal:  Arthritis Res Ther       Date:  2020-03-30       Impact factor: 5.156

Review 9.  Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?

Authors:  Devis Benfaremo; Armando Gabrielli
Journal:  Cells       Date:  2019-12-27       Impact factor: 6.600

10.  Bacterial Lipoproteins Induce BAFF Production via TLR2/MyD88/JNK Signaling Pathways in Dendritic Cells.

Authors:  Jintaek Im; Jung Eun Baik; Dongwook Lee; Ok-Jin Park; Dong Hyun Park; Cheol-Heui Yun; Seung Hyun Han
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.